EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy

Zhensheng Li, Liang Chen, Huina Han, Yuguang Shang, Yue Li, Zhifeng Jia, Yunjiang Liu

Oncology Research and Treatment · 2024

DOI: 10.1159/000543137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Zhensheng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Bone Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bone-only metastasis (BOM) is a distinct clinical phenomenon in which cancer cells disseminate exclusively to the bones, without involvement of other distant organs. We investigated the factors associated with the BOM state versus other states of metastasis in breast cancer patients with bone metastasis (BM) at their first relapse. The results could help tailor the screening and preventive therapy strategies for BM in breast cancer.

Methods

The study included 231 women who underwent mastectomy for primary unilateral non-metastatic breast cancer in 1997 or later and were subsequently diagnosed with BM at first relapse in 2008–2018 at the Fourth Hospital of Hebei Medical University in China. Factors such as patient age at primary breast cancer diagnosis, tumor clinicopathological characteristics, chemotherapy, radiotherapy, endocrine therapy (ET), time to progression (TTP), and others were analyzed. ET compliance was categorized from medication adherence. Multivariate logistic regressions were used to estimate the odds ratio (OR) and p value.

Results

Only three (3.8%, 3/79) human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients (n = 79) used anti-HER2-targeted agents in the adjuvant setting. After excluding them, the remaining 228 patients were analyzed. They had an average age of 47.3 years and median TTP 29.4 months at their first relapse. Overall, patients with BOM accounted for 26.8%. The BOM state was similarly presented in the hormone receptor-positive (HR+) patients (n = 182) and in the HR-negative (HR−) patients (n = 45) (28.6% vs. 17.8%, p = 0.142). However, it was significantly lower in the HER2+ patients (n = 76) than in the HER2-negative (HER2−) patients (n = 129) (13.2% vs. 31.8%, p = 0.003). Multivariate analyses showed that the BOM state was not associated with the HR+ (vs. HR−, OR 1.253, p = 0.723) and full ET compliance (vs. no/partial, OR 1.346, p = 0.545) status. Nonetheless, the BOM state was significantly associated with a lower chance in the HER2+ patients overall (OR 0.240, p = 0.008) and in the HR+ patients (OR 0.145, p = 0.005) but not in the HR− patients (OR 1.012, p = 0.991) than one in the HER2− patients. A lower chance of BOM state was also associated with TTP ≥24 months (p < 0.05). There were no other associated factors identified.

Conclusion

Differently from HR status and other clinicopathological factors, the HER2+ status is associated with a lower chance of the BOM state in breast cancer patients with first BM. Such association appears to be reflected in HR+ patients only.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesBone NeoplasmsHumansFemaleMiddle AgedAdultChinaAgedMastectomyRetrospective StudiesRisk FactorsNeoplasm Recurrence, LocalMolecular Targeted TherapyEast Asian People

Stichwörter der Autor:innen

Bone metastasisBone-only metastasisBreast cancerEndocrine therapyHER2Hormone receptor

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Surgery, Hebei Chest Hospital, Shijiazhuang, China.
  • Department of Oncology, The Fourth Hospital of Shijiazhuang City, Shijiazhuang, China.
  • Department of Orthopedic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Zitieren

APA

Li, Z., Chen, L., Han, H., Shang, Y., Li, Y., Jia, Z., & Liu, Y. (2024). Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy. Oncology Research and Treatment. https://doi.org/10.1159/000543137

Vancouver

Li Z, Chen L, Han H, Shang Y, Li Y, Jia Z, et al. Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy. Oncology Research and Treatment. 2024. doi:10.1159/000543137

BibTeX
@article{Li2024,
  author = {Li, Zhensheng and Chen, Liang and Han, Huina and Shang, Yuguang and Li, Yue and Jia, Zhifeng and Liu, Yunjiang},
  title = {Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy},
  journal = {Oncology Research and Treatment},
  year = {2024},
  doi = {10.1159/000543137}
}
Kostenlos starten →